Status:

RECRUITING

Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches

Lead Sponsor:

University Health Network, Toronto

Collaborating Sponsors:

The Canadian Pain Society

Pfizer

Conditions:

Chronic Daily Headache

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

Chronic daily headaches (CDH) poses a significant burden on patients, healthcare systems and the society. Intravenous (IV) ketamine infusion, an intervention that is widely available and scalable, can...

Detailed Description

The KetHead study is designed as a multi-center, placebo-controlled, superiority randomized controlled trial with two parallel groups and blinding of participants and outcome assessors. It will be con...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Age 18-75 years
  • CDH diagnosis preceding trial enrollment with headache episodes lasting for 4 or more hours occurring on 15 or more days in a month for 3 or more months (International Headache Society-IHS criteria)
  • Normal liver and kidney function tests
  • Exclusion criteria:
  • Pregnant or breastfeeding patients
  • Pre-existing renal impairment
  • Pre-existing liver impairment
  • Chronic benzodiazepine or antipsychotic medication use
  • History of cerebrovascular event
  • Significant and untreated hypertension or severe cardiac condition
  • Hypothyroidism
  • Glaucoma
  • Concomitant use of strong CYP2B6 or CYP2C8 inhibitor
  • Allergy or intolerance to ketamine
  • Pheochromocytoma
  • Any significant cognitive or language barriers that impede participation
  • CGRP antagonist use in 1 month or Onabotulinum-toxin A 3 months before infusion
  • Active diagnosis of Post-Traumatic Stress Disorder (PTSD)
  • Active diagnosis of Substance Use Disorder
  • Patients taking opioid medications with daily Oral Morphine Equivalents ≥80 mg

Exclusion

    Key Trial Info

    Start Date :

    June 1 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    June 1 2026

    Estimated Enrollment :

    56 Patients enrolled

    Trial Details

    Trial ID

    NCT05306899

    Start Date

    June 1 2022

    End Date

    June 1 2026

    Last Update

    November 17 2025

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Women's College Hospital

    Toronto, Ontario, Canada, M5S 1B2

    2

    Toronto Western Hospital

    Toronto, Ontario, Canada, M5T 2S8

    Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches | DecenTrialz